pharmaphorum3y
China's insulin plans will hit 2022 revenues, says Novo Nordisk
and Xultophy (insulin degludec/liraglutide). That suggests its top-selling insulin products like rapid-acting NovoRapid (insulin aspart), premix NovoMix (insulin aspart/insulin aspart protamine ...
INHALE-3 extension study: Inhaled technosphere insulin plus insulin degludec maintains glycemic control
A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...
Study suggests inhaled technosphere insulin could be considered as an option for adults with type 1 diabetes
A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) should be considered as an option for individuals with type 1 diabetes who want ...
pharmaphorum8y
Sanofi GLP-1 finally approved in US
combining long-acting insulin Tresiba (insulin degludec) with Victoza. Zealand Pharma is also set to receive a $5 million milestone payment, and could receive up to $135 million more, plus ...